Literature DB >> 20635527

Assay of tolnaftate in human skin samples after in vitro penetration studies using high performance liquid chromatography.

Toma Kezutyte1, Olga Kornysova, Audrius Maruska, Vitalis Briedis.   

Abstract

Abstract: Tolnaftate, an antifungal of thiocarbamate class, is used topically in 1% formulations. Its penetration into skin layers is a prerequisite for tolnaftate action against dermatophytes. The aim of this work was to optimize and validate a simple, rapid, accurate and reproducible procedure for tolnaftate assay in human skin samples and to apply this procedure for in vitro tolnaftate penetration studies. High performance liquid chromatography (HPLC) method with UV detection was used to validate tolnaftate assay for linearity, specificity, accuracy, precision, limit of quantitation, limit of detection, drug extraction recovery and stability in skin extracts. In vitro tolnaftate penetration studies were carried out using flow-through diffusion cells, mounted with human skin. Epidermis and dermis, separated by heat-separation method, were extracted using ultrasonication in methanol. Linear range of the analytical procedure was within 0.6-100 pg/mL. The assay was specific, accurate (within-day and between-day recovery values were 98.2-104.2% and 98.7-101.4%, respectively) and precise (within-day and between-day imprecision was = 3.8%). Mean extraction recoveries of tolnaftate from epidermis and dermis were satisfactory and reaching 90%. In vitro skin penetration studies revealed that after application of 1% (w/w) tolnaftate solution in polyethylene glycol 400 for 24 hours, the mean amount of tolnaftate penetrating into the epidermis and dermis was 2.60 +/- 0.28 microg/cm2 and 0.92 +/- 0.12 microg/cm2, respectively. A validated reliable HPLC method could be recommended for biopharmaceutical evaluation of tolnaftate preparations and studies of pharmacokinetics in human skin after in vitro penetration studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635527

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  6 in total

1.  Formulation of Propolis Phenolic Acids Containing Microemulsions and Their Biopharmaceutical Characterization.

Authors:  Modestas Žilius; Kristina Ramanauskienė; Vaida Juškaitė; Vitalis Briedis
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-03       Impact factor: 2.629

2.  Application of Confocal Raman Microscopy for the Characterization of Topical Semisolid Formulations and their Penetration into Human Skin Ex Vivo.

Authors:  Nathalie Jung; Sarika Namjoshi; Yousuf Mohammed; Jeffrey E Grice; Heather A E Benson; Sam G Raney; Michael S Roberts; Maike Windbergs
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

3.  Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment.

Authors:  Diana Aziz; Sally Mohamed; Saadia Tayel; Amal Makhlouf
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study.

Authors:  Diana Aziz; Sally A Mohamed; Saadia Tayel; Amal Makhlouf
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

5.  Release of propolis phenolic acids from semisolid formulations and their penetration into the human skin in vitro.

Authors:  Modestas Zilius; Kristina Ramanauskienė; Vitalis Briedis
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-23       Impact factor: 2.629

6.  Design and Formulation of Optimized Microemulsions for Dermal Delivery of Resveratrol.

Authors:  Vaida Juškaitė; Kristina Ramanauskienė; Vitalis Briedis
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-31       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.